디지털 바이오제조 시장 : 기술 유형별, 도입 옵션별, 제조되는 생물제제 유형별, 주요 지역별 - 업계 동향과 세계 예측(-2035년)

Digital Biomanufacturing Market by Type of Technology, Deployment Options, Type of Biologic Manufactured, and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,928,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,105,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,302,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,986,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 디지털 바이오제조 시장 규모는 2035년까지의 예측 기간 중 17.9%의 CAGR로 확대하며, 현재 20억 달러에서 2035년까지 123억 달러로 성장할 것으로 예측됩니다.

디지털 바이오제조는 바이오 제조 프로세스 전체의 개선을 촉진하기 위해 프로세스 분석 기술(PAT), 데이터 분석 소프트웨어(DAS), 제조 실행 시스템(MES), 디지털 트윈 등 다양한 디지털 소프트웨어나 플랫폼을 채택하고 있습니다. 디지털 바이오 제조 접근 방식을 사용하면 절차의 생산성이 향상되고 기존 인프라의 수명이 연장되는 것으로 입증되었습니다. 데이터 분석 및 데이터 과학의 발전으로 바이오 제조 공정의 현대화는 AI 및 디지털 트윈과 같은 혁신적인 기술은 사업 운영의 미래 가능성을 높이고, 비용 증가, 규제 지침 강화, 수익성 악화 등 다양한 문제를 해결하기 위해 바이오제약 기업의 전략에 필수적인 요소입니다. 바이오제약 기업의 전략에 필수적인 요소로 자리 잡고 있습니다.

현재 시장 동향과 기술 혁신을 고려할 때, 차세대 머신러닝 기술은 실시간 모니터링 및 예측 분석을 위해 고급 데이터 분석, 프로세스 및 장비 모델링과 통합되어 종합적인 시스템을 형성할 것으로 예상됩니다. 승인된 생물제제의 수 증가, 이에 따른 생물제제 전문 임상시험의 수 증가, 연구개발 활동의 활성화, 클라우드 및 IoT 기반 공정 기술의 인기 증가에 힘입어 디지털 바이오 제조 산업은 향후 수년간 꾸준한 성장을 이룰 것으로 예상됩니다.

현재 100개 이상의 기업이 바이오의약품 수요 증가에 대응하기 위해 다양하고 참신한 디지털 바이오 제조 솔루션을 제공하고 있다고 주장하고 있습니다.

140개 이상의 플랫폼이 PAT, DAS, MES, 디지털 트윈, 기타 기술에 기반하여 생물제제 제조 프로세스의 디지털화를 위해 제공되고 있습니다. 프로세스 분석 기술의 85% 이상은 공정 자동화, 바이오프로세스의 최적화 및 제어를 제공할 수 있으며, 이들 플랫폼의 대부분은 단백질 및 항체 제조를 지원하고 있습니다. 데이터 분석 소프트웨어는 프로세스 인텔리전스 및 데이터 통합을 포함한 광범위한 기술 역량을 제공합니다. 주로 이러한 플랫폼은 인공지능 기반 프로그램과 호환됩니다. 전문 지식을 활용하여 약 80%의 기업이 클라우드 기반 MES 솔루션을 제공합니다. 이 솔루션은 생산 추적, 성능 분석, 데이터 통합 기능을 수행하기 위해 다양한 유형의 소프트웨어와 통합할 수 있습니다.

세계의 디지털 바이오제조 시장에 대해 조사했으며, 시장의 개요와 기술 유형별, 도입 옵션별, 제조되는 생물제제 유형별, 주요 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 개요

제3장 서론

제4장 시장 구도

제5장 기술 경쟁력 분석

제6장 기업 개요

• 챕터 개요
• AspenTech
• FUJIFILM Diosynth Biotechnologies
• Merck
• Thermo Fisher Scientific
• Bioreactors.net
• Sartorius
• Dassault Systemes
• GE Healthcare
• Korber

제7장 벤치마크 분석

제8장 파트너십과 협업

제9장 시장 집중 분석

제10장 산업 수명주기 분석

제11장 시장 예측과 기회 분석

• 챕터 개요
• 예측 조사 방법과 주요 전제
• 세계의 디지털 바이오제조 시장, 2035년까지
• 디지털 바이오제조 시장 : 기술 유형별 분석
• 디지털 바이오제조 시장 : 도입 옵션별 분석
• 디지털 바이오제조 시장 : 제조되는 생물제제 유형별 분석
• 디지털 바이오제조 시장 : 지역별 분석

제12장 결론

제13장 인터뷰 기록

제14장 부록 I : 표 형식 데이터

제15장 부록 II : 기업 및 단체 리스트

KSA

영문 목차

영문목차

DIGITAL BIOMANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global digital biomanufacturing market is estimated to grow from USD 2 billion in the current year to USD 12.3 billion by 2035, at a CAGR of 17.9% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Technology

• Process Analytical Technology (PAT)
• Data Analysis Software (DAS)
• Manufacturing Execution Systems (MES)
• Digital Twins

Deployment Options

• Cloud-based
• On-premises

Type(s) of Biologic(s)Manufactured

• Antibodies
• Cell and Gene Therapies
• Proteins
• Vaccines
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

DIGITAL BIOMANUFACTURING MARKET: GROWTH AND TRENDS

Digital biomanufacturing employs various digital software and platforms, such as process analytical technology (PAT), data analysis software (DAS), manufacturing execution system (MES) and digital twin, to facilitate improvement in the overall biomanufacturing process. It has been demonstrated that the use of digital biomanufacturing approaches can boost the productivity of procedures and the longevity of existing infrastructure. The modernization of the biomanufacturing process has been more visible and successful due to advancements in data analytics and data science. Innovative technologies, such as AI and digital twins, have become an integral part of biopharmaceutical companies' strategy to future-proof their business operations and address various issues, including growing expenses, stringent regulatory guidelines and deteriorating profit margins.

Considering the current market trends and innovation, it is anticipated that the next generation of machine learning technologies will be integrated with advanced data analytics, and process and equipment modeling to form comprehensive systems, for the purpose of real-time monitoring and predictive analysis. Driven by the increasing number of biologics approved, consequent growth in the number of biologics-focused clinical trials, rise in R&D activity and rising popularity of cloud and IoT based process technologies, the digital biomanufacturing industry is expected to witness steady growth over the coming years.

DIGITAL BIOMANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the digital biomanufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Currently, over 100 firms claim to offer a variety of novel digital biomanufacturing solutions in order to cater to the rising demand for biopharmaceuticals.

• 140+ platforms, based on PAT, DAS, MES, digital twins and other such technologies, are being offered for digitalization of the biologic production process.
• Over 85% of the process analytical technologies are capable of offering process automation and bioprocess optimization and controls, majority of these platforms support the manufacturing of proteins and antibodies.
• Data analysis software offers a wide spectrum of technical competencies, including process intelligence and data integration; predominantly, these platforms are compatible with artificial intelligence-based programs.
• Leveraging their expertise, ~80% of players are offering cloud-based MES solutions that can be integrated with numerous types of software to carry out production tracking, performance analysis and data integration functions.
• The developer landscape is dominated by the presence of established players; asset / process management emerged as the prominent application areas for digital twin technologies.
• In pursuit of gaining a competitive edge, digital biomanufacturing providers are upgrading their existing software capabilities and enhancing their biologic focused technology portfolios.
• The growing preference for digitalization of bioprocessing is evident from the rise in partnership activity; it is worth highlighting that more than 80% of the deals were forged in the last three years.
• The adoption of digital biomanufacturing solutions has increased considerably in recent years; white spaces in this domain present significant growth opportunities for innovators.
• Fundamental advancements in the field of smart biomanufacturing will promote process robustness and product quality; this will inevitably culminate in accelerated growth of the market.
• Driven by continuous technological innovations, this domain is anticipated to witness steady growth; technologies focused on digital twins are expected to gain significant traction with an annualized growth of 19%.

DIGITAL BIOMANUFACTURING MARKET: KEY SEGMENTS

Digital Twins is the Fastest Growing Segment of the Digital Biomanufacturing Market

Based on the type of technology, the market is segmented into process analytical technology, data analysis software, manufacturing execution system and digital twin. At present, the process analytical technology segment holds the maximum share of the digital biomanufacturing market. It is worth highlighting that the digital biomanufacturing market for digital twins is likely to grow at a relatively higher CAGR.

Currently, the On-premises Segment Occupies the Largest Share of the Digital Biomanufacturing Market

Based on the deployment options, the market is segmented into cloud-based and on-premises. Currently, the on-premises segment holds the maximum share of the digital biomanufacturing market. It is worth highlighting that the digital biomanufacturing market for cloud-based deployment option is likely to grow at a relatively higher CAGR.

Cell Therapies and Gene Therapies are the Fastest Growing Segment of the Digital Biomanufacturing Market During the Forecast Period

Based on the type of biologic(s) manufactured, the market is segmented into antibodies, cell therapies and gene therapies, proteins, vaccines, and others. At present, the antibody segment holds the maximum share of the digital biomanufacturing market. It is worth highlighting that the digital biomanufacturing market for cell therapies and gene therapies is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. The majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Digital Biomanufacturing Market

• AspenTech
• Bioreactors.net
• Dassault Systemes
• FUJIFILM Diosynth Biotechnologies
• GE Healthcare
• Korber
• Merck
• Sartorius
• Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer and President, BioIntelligence Technologies
• Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology
• Vice President of Operations and Strategic Initiatives, Aizon
• Director, Business Development and Channel Sales, and Quality and Manufacturing Digitization Specialist, MasterControl
• Director of Sales, Trunovate
• Business Consultant, Dassault Systemes

DIGITAL BIOMANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the digital biomanufacturing market, focusing on key market segments, including [A] type of technology, [B] deployment options, [C] types of biologics manufactured and [D] key geographical regions.
• Market Landscape: A comprehensive evaluation of digital biomanufacturing companies (offering digital biomanufacturing technologies - Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] type of company, [E] number of platforms offered, [F] deployment options, [G] platform capabilities, [H] software capabilities, [I] type(s) of biologic(s) manufactured, [J] other compatible platforms, [K] type of end user(s), [L] integrating software, [M] manufacturing operation management (MOM), [N] product lifecycle management (PLM), [O] human resource management (HRM)), [P] type of service(s) offered and [Q] area(s) of application.
• Technology Competitiveness Analysis: A comprehensive competitive analysis of digital biomanufacturing technologies, examining factors, such as [A] supplier strength, [B] technology portfolio and [C] type(s) of biologic(s) manufactured.
• Company Profiles: In-depth profiles of key industry players offering digital biomanufacturing technologies, focusing on [A] company overviews, [B] capabilities of digital technologies offered by these firms, [C] recent developments and [D] an informed future outlook.
• Competitive Benchmarking Analysis: A competitive benchmarking analysis highlighting the existing capabilities companies, across key peer groups.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, based on multiple relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of technology, [D] most active players (in terms of number of deals inked) and [E] regional distribution of partnership activity.
• Market Concentration Analysis: A detailed analysis highlighting the market concentration of key industry stakeholders across various regions, based on prevalent parameters, such as [A] years of entrance, [B] company size, [C] type of technology, [D] number of platforms offered and [E] number of partnerships inked.
• Industry Lifecycle Analysis: A comprehensive analysis of the digital biomanufacturing industry that outlines its various stages, such as emergence, growth, maturation and decline. This analysis aims to enhance understanding of the current phase of the industry on the lifecycle chart based on historical trends, partnership dynamics, and investments made by stakeholders in this field. Additionally, it highlights the impact of key factors that are likely to drive the growth of the market. The report also discusses both short-term and long-term effects of key factors anticipated to significantly influence the broader adoption of digitalization in the field of biomanufacturing.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of Digital Biomanufacturing in Healthcare
• 3.3. Emerging Technologies that Support Digital Biomanufacturing
  • 3.3.1. Process Analytical Technology (PAT)
  • 3.3.2. Data Analysis Software (DAS)
  • 3.3.3. Bioprocess Digital Twins
  • 3.3.4. Manufacturing Execution Systems (MES)
• 3.4. Challenges Associated with the Adoption of Digital Biomanufacturing
• 3.5. Future Perspectives

4. MARKERT LANDSCAPE

• 4.1. Chapter Overview
• 4.2. List of Process Analytical Technology (PAT) Providers
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters (Region-wise)
  • 4.2.4. Analysis by Location of Headquarters (Country-wise)
  • 4.2.5. Analysis by Type of Company
  • 4.2.6. Analysis by Number of Platforms Offered
  • 4.2.7. Analysis by Deployment Options
  • 4.2.8. Analysis by Platform Capabilities
  • 4.2.9. Analysis by Type(s) of Biologic(s) Manufactured
  • 4.2.10. Analysis by Other Compatible Platforms
  • 4.2.11. Analysis by Type of End User(s)
  • 4.2.12. Analysis by Year of Establishment, Location of Headquarters and Platform Capabilities
  • 4.2.13. Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
• 4.3. List of Data Analysis Software (DAS) Providers
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters (Region-wise)
  • 4.3.4. Analysis by Location of Headquarters (Country-wise)
  • 4.3.5. Analysis by Type of Company
  • 4.3.6. Analysis by Number of Software Offered
  • 4.3.7. Analysis by Deployment Options
  • 4.3.8. Analysis by Software Capabilities
  • 4.3.9. Analysis by Other Compatible Platforms
  • 4.3.10. Analysis by Type of End User(s)
  • 4.3.11. Analysis by Year of Establishment, Location of Headquarters and Software Capabilities
  • 4.3.12. Analysis by Years of Experience, Location of Headquarters and Number of Software Capabilities (Dot-Plot Representation)
• 4.4. List of Manufacturing Execution Systems (MES) Providers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Location of Headquarters (Region-wise)
  • 4.4.4. Analysis by Location of Headquarters (Country-wise)
  • 4.4.5. Analysis by Type of Company
  • 4.4.6. Analysis by Number of Platforms Offered
  • 4.4.7. Analysis by Deployment Options
  • 4.4.8. Analysis by Platform Capabilities
  • 4.4.9. Analysis by Integrating Software
  • 4.4.10. Analysis by Type of Service(s) Offered
  • 4.4.11. Analysis by Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
• 4.5. List of Digital Twins Providers
  • 4.5.1. Analysis by Year of Establishment
  • 4.5.2. Analysis by Company Size
  • 4.5.3. Analysis by Location of Headquarters (Region-wise)
  • 4.5.4. Analysis by Location of Headquarters (Country-wise)
  • 4.5.5. Analysis by Number of Platforms Offered
  • 4.5.6. Analysis by Area(s) of Application
  • 4.5.7. Analysis by Type of End User(s)
  • 4.5.8. Analysis by Years of Experience, Location of Headquarters and Area(s) of Application (Dot-Plot Representation)

5. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Methodology
• 5.3. Digital Biomanufacturing: Competitiveness Analysis
• 5.4. Assumptions and Key Parameters for PAT Technologies
  • 5.4.1. Technology Competitiveness Analysis: Process Analytical Technologies Offered by Small Companies
  • 5.4.2. Technology Competitiveness Analysis: Process Analytical Technologies Offered by Mid-sized Companies
  • 5.4.3. Technology Competitiveness Analysis: Process Analytical Technologies Offered by Large Companies
  • 5.4.4. Technology Competitiveness Analysis: Process Analytical Technologies Offered by Very Large Companies
• 5.5. Assumptions and Key Parameters for DAS Technologies
  • 5.5.1 Technology Competitiveness Analysis: Data Analysis Software
• 5.6. Assumptions and Key Parameters for MES Technologies
  • 5.6.1. Technology Competitiveness Analysis: Manufacturing Execution Systems Offered by Small Companies
  • 5.6.2. Technology Competitiveness Analysis: Manufacturing Execution Systems Offered by Mid-sized Companies
  • 5.6.3. Technology Competitiveness Analysis: Manufacturing Execution Systems Offered by Large and Very Large Companies
• 5.7. Assumptions and Key Parameters for Digital Twins
  • 5.7.1 Technology Competitiveness Analysis: Digital Twins

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. AspenTech
  • 6.2.1. Company Overview
  • 6.2.2. Financial Information
  • 6.2.3. Technology Portfolio
  • 6.2.4. Recent Developments and Future Outlook
• 6.3. FUJIFILM Diosynth Biotechnologies
  • 6.3.1. Company Overview
  • 6.3.2. Financial Information
  • 6.3.3. Technology Portfolio
  • 6.3.4. Recent Developments and Future Outlook
• 6.4. Merck
  • 6.4.1. Company Overview
  • 6.4.2. Financial Information
  • 6.4.3. Technology Portfolio
  • 6.4.4. Recent Developments and Future Outlook
• 6.5. Thermo Fisher Scientific
  • 6.5.1. Company Overview
  • 6.5.2. Financial Information
  • 6.5.3. Technology Portfolio
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Bioreactors.net
  • 6.6.1. Company Overview
  • 6.6.2. Technology Portfolio
  • 6.6.3. Recent Developments and Future Outlook
• 6.7. Sartorius
  • 6.7.1. Company Overview
  • 6.7.2. Financial Information
  • 6.7.3. Technology Portfolio
  • 6.7.4. Recent Developments and Future Outlook
• 6.8. Dassault Systemes
  • 6.8.1. Company Overview
  • 6.8.2. Financial Information
  • 6.8.3. Area(s) of Application
  • 6.8.4. Recent Developments and Future Outlook
• 6.9. GE Healthcare
  • 6.9.1. Company Overview
  • 6.9.2. Technology Portfolio
  • 6.9.3. Recent Developments and Future Outlook
• 6.10. Korber
  • 6.10.1. Company Overview
  • 6.10.2. Financial Information
  • 6.10.3. Technology Portfolio
  • 6.10.4. Recent Developments and Future Outlook

7. BENCHMARKING ANALYSIS

• 7.1. Chapter Overview
• 7.2. Methodology and Key Assumptions
• 7.3. Competitive Benchmarking by Company Size and Region
  • 7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
  • 7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
  • 7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
  • 7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
  • 7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
  • 7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
  • 7.3.7. Competitive Benchmarking: Small, Mid-sized and Very Large Players based in Asia-Pacific (Peer Group VII)
• 7.4. Competitive Benchmarking: Pockets of Innovation and White Spaces

8. PARTNERSHIPS AND COLLABORATIONS

• 8.1. Chapter Overview
• 8.2. Partnership Models
• 8.3. Digital Biomanufacturing: List of Partnerships and Collaborations
  • 8.3.1. Analysis by Year of Partnership
  • 8.3.2. Analysis by Type of Partnership
  • 8.3.3. Analysis by Year and Type of Partnership
  • 8.3.4. Analysis by Type of Technology
  • 8.3.5. Analysis by Year of Partnership and Type of Technology
  • 8.3.6. Most Active Players: Analysis by Number of Partnerships
  • 8.3.7. Analysis by Geography
    • 8.3.7.1. Intracontinental and Intercontinental Agreements
    • 8.3.7.2. International and Local Agreements

9. MARKET CONCENTRATION ANALYSIS

• 9.1. Chapter Overview
• 9.2. Assumptions and Key Parameters
• 9.3. Methodology
• 9.4. Market Concentration Analysis: Top Digital Biomanufacturing Providers

10. INDUSTRY LIFECYCLE ANALYSIS

• 10.1. Chapter Overview
• 10.2. Industry Lifecycle Analysis
• 10.3. Digital Biomanufacturing: Historical Timeline of Key Events
• 10.4. Digital Biomanufacturing: Start-up Activity
• 10.5. Digital Biomanufacturing: Established Players Activity
• 10.6. Digital Biomanufacturing: Partnership and Collaboration Trends
• 10.7. Digital Biomanufacturing: Funding and Investments Trends
• 10.8. Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
• 10.9. Future Outlook of Digital Biomanufacturing
• 10.10. Industry Lifecycle Analysis: Digital Biomanufacturing

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Forecast Methodology and Key Assumptions
• 11.3. Global Digital Biomanufacturing Market, till 2035
• 11.4. Digital Biomanufacturing Market: Analysis by Type of Technology
  • 11.4.1. Digital Biomanufacturing Market for PAT, till 2035
  • 11.4.2. Digital Biomanufacturing Market for DAS, till 2035
  • 11.4.3. Digital Biomanufacturing Market for MES, till 2035
  • 11.4.4. Digital Biomanufacturing Market for Digital Twins, till 2035
• 11.5. Digital Biomanufacturing Market: Analysis by Type of Deployment Options
  • 11.5.1. Digital Biomanufacturing Market for Cloud-based Deployment Options, till 2035
  • 11.5.2. Digital Biomanufacturing Market for On-premises Deployment Options, till 2035
• 11.6. Digital Biomanufacturing Market: Analysis by Type(s) of Biologic(s) Manufactured
  • 11.6.1. Digital Biomanufacturing Market for Antibodies, till 2035
  • 11.6.2. Digital Biomanufacturing Market for Cell and Gene Therapies, till 2035
  • 11.6.3. Digital Biomanufacturing Market for Proteins, till 2035
  • 11.6.4. Digital Biomanufacturing Market for Vaccines, till 2035
  • 11.6.5. Digital Biomanufacturing Market for Others, till 2035
• 11.7. Digital Biomanufacturing Market: Analysis by Geography
  • 11.7.1. Digital Biomanufacturing Market in North America, till 2035
  • 11.7.2. Digital Biomanufacturing Market in Europe, till 2035
  • 11.7.3. Digital Biomanufacturing Market in Asia-Pacific, till 2035
  • 11.7.4. Digital Biomanufacturing Market in Latin America, till 2035
  • 11.7.5. Digital Biomanufacturing Market in Middle East and North Africa, till 2035

12. CONCLUDING REMARKS

13. INTERVIEW TRANSCRIPTS

• 13.1. Chapter Overview
• 13.2. BioIntelligence Technologies
  • 13.2.1. Interview Transcript: Chief Executive Officer and President
• 13.2. Yokogawa Insilico Biotechnology
  • 13.2.1. Interview Transcript: Managing Director and Chief Executive Officer
• 13.3. MasterControl
  • 13.3.1. Interview Transcript: Director, Business Development and Channel Sales, and Quality and Manufacturing Digitization Specialist
• 13.4. Trunovate
  • 13.4.1. Interview Transcript: Director of Sales
• 13.5. Dassault Systemes
  • 13.5.1. Interview Transcript: Business Consultant

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료